insights_auto
Nega ADAPY tushdi 2,99%?
Batafsil oʻrganishchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
0,026Â US$
arrow_downward
-2,99%(-0,00080) 1K
29-sen, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoADAPY tikeri uchun statistika yaratilmoqda...
Ochish
0,02Â US$
Yuqori
0,03Â US$
Past
0,02Â US$
Bozor kapitali
6,16Â mln
Oʻrtacha hajm
164,89Â ming
Hajmi
93,84Â ming
52 haftalik eng yuqori
0,28Â US$
52 haftalik eng past
0,00Â US$
Beta
0,83
Muomaladagi aksiyalar
265,05Â mln
Xodimlar soni
272
Ochish
0,02Â US$
Yuqori
0,03Â US$
Past
0,02Â US$
Bozor kapitali
6,16Â mln
Oʻrtacha hajm
164,89Â ming
Hajmi
93,84Â ming
52 haftalik eng yuqori
0,28Â US$
52 haftalik eng past
0,00Â US$
Beta
0,83
Muomaladagi aksiyalar
265,05Â mln
Xodimlar soni
272
Profil
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Adaptimmune Therapeutics PLC - ADR haqida